9 assets in T-Cell Prolymphocytic Leukemia

Therapeutic assets addressing T-Cell Prolymphocytic Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ruxolitinib T-Cell Prolymphocytic Leukemia	Jonathan Brammer	P2	B (59)
Apg 115 T-Cell Prolymphocytic Leukemia	Ascentage Pharma Group Inc.	P2	CCC (53)
Lisaftoclax T-Cell Prolymphocytic Leukemia	Ascentage Pharma Group Inc.	P2	CCC (53)
Duvelisib T-Cell Prolymphocytic Leukemia	Jonsson Comprehensive Cancer Center	P1/2	CCC (52)
Venetoclax T-Cell Prolymphocytic Leukemia	Jonsson Comprehensive Cancer Center	P1/2	CCC (48)
lp-118 T-Cell Prolymphocytic Leukemia	Newave Pharmaceutical Inc	P1	CC (43)
Wu-Cart-007 T-Cell Prolymphocytic Leukemia	Washington University School of Medicine	P1	CC (43)
Itacitinib T-Cell Prolymphocytic Leukemia	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P1	CC (41)
kt-333 T-Cell Prolymphocytic Leukemia	Kymera Therapeutics, Inc.	P1	NR ()